- Home
- SDRL vs TARS Comparison
SDRL vs TARS Comparison
Compare SDRL & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDRL
- TARS
- Stock Information
- Founded
- SDRL 2005
- TARS 2016
- Country
- SDRL Bermuda
- TARS United States
- Employees
- SDRL N/A
- TARS N/A
- Industry
- SDRL Oil & Gas Production
- TARS Medicinal Chemicals and Botanical Products
- Sector
- SDRL Energy
- TARS Health Care
- Exchange
- SDRL Nasdaq
- TARS Nasdaq
- Market Cap
- SDRL 2.0B
- TARS 1.7B
- IPO Year
- SDRL N/A
- TARS 2020
- Fundamental
- Price
- SDRL $32.78
- TARS $57.63
- Analyst Decision
- SDRL Strong Buy
- TARS Strong Buy
- Analyst Count
- SDRL 4
- TARS 7
- Target Price
- SDRL $56.67
- TARS $67.14
- AVG Volume (30 Days)
- SDRL 808.3K
- TARS 630.9K
- Earning Date
- SDRL 08-06-2025
- TARS 08-06-2025
- Dividend Yield
- SDRL N/A
- TARS N/A
- EPS Growth
- SDRL N/A
- TARS N/A
- EPS
- SDRL 1.21
- TARS N/A
- Revenue
- SDRL $1,289,000,000.00
- TARS $295,521,000.00
- Revenue This Year
- SDRL $4.64
- TARS $33,170.29
- Revenue Next Year
- SDRL $1.16
- TARS N/A
- P/E Ratio
- SDRL $27.00
- TARS N/A
- Revenue Growth
- SDRL N/A
- TARS 254.45
- 52 Week Low
- SDRL $17.74
- TARS $27.18
- 52 Week High
- SDRL $42.41
- TARS $59.76
- Technical
- Relative Strength Index (RSI)
- SDRL 67.08
- TARS 69.92
- Support Level
- SDRL $30.56
- TARS $57.00
- Resistance Level
- SDRL $33.38
- TARS $59.76
- Average True Range (ATR)
- SDRL 1.08
- TARS 1.74
- MACD
- SDRL 0.25
- TARS -0.26
- Stochastic Oscillator
- SDRL 87.85
- TARS 67.78
About SDRL Seadrill Limited
Seadrill Ltd is an offshore drilling contractor company. The company is engaged in providing offshore drilling services to the oil and gas industry. The primary business of the company is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deepwater areas in both benign and harsh environments. The geographical segments of the company are the United States, Brazil, Angola, Norway, Canada and others. The company derives maximum revenue from the United States.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.